8-Hydroxy-3,8-dimethyl-3-aza-bicyclo<3.2.1>octan | 4075-30-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 8-Hydroxy-3,8-dimethyl-3-aza-bicyclo<3.2.1>octan
• 英文别名: 3,8-Dimethyl-3-azabicyclo[3.2.1]octan-8-ol；3,8-dimethyl-3-azabicyclo[3.2.1]octan-8-ol
• CAS: 4075-30-3
• 化学式: C₉H₁₇NO
• 分子量: 155.24
• InChiKey: UTJGFQGERGHDTF-UHFFFAOYSA-N

文献信息

• [EN] ANTICANCER COMPOUNDS<br/>[FR] COMPOSÉS ANTICANCÉREUX
  申请人：UNIV CALIFORNIA

  公开号：WO2022261204A1

  公开（公告）日：2022-12-15

  Disclosed are compounds of formula (I): formula (I) and pharmaceutically acceptable salts thereof. The compounds of the invention are BDII- selective inhibitors of BET proteins, and have therapeutic potential for treating cancer, acute kidney disease, and viral infections, among other diseases.

  本发明涉及以下公式（I）的化合物：公式（I）及其药学上可接受的盐。本发明的化合物是BET蛋白的BDII选择性抑制剂，具有治疗癌症、急性肾脏疾病、病毒感染等疾病的治疗潜力。
• SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS
  申请人：Repare Therapeutics Inc.

  公开号：US20220185809A1

  公开（公告）日：2022-06-16

  Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.
• [EN] USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS<br/>[FR] UTILISATION D'INHIBITEURS D'ATR EN ASSOCIATION AVEC DES INHIBITEURS DE PARP
  申请人：REPARE THERAPEUTICS INC

  公开号：WO2021119523A1

  公开（公告）日：2021-06-17

  Disclosed are methods of treating a cancer in a subject using an ATR inhibitor and PARP inhibitor, wherein the cancer has been previously identified as a cancer having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or as an ALT+ cancer. Also disclosed are methods of inducing cell death in an aberrant cancer cell having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or an ALT+ cancer cell, by contacting the cell with an effective amount of an ATR inhibitor and PARP inhibitor.
• [EN] USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS FOR TREATING CANCER<br/>[FR] UTILISATION D'INHIBITEURS D'ATR EN ASSOCIATION AVEC DES INHIBITEURS DE PARP POUR LE TRAITEMENT DU CANCER
  申请人：[en]REPARE THERAPEUTICS INC.

  公开号：WO2022261777A1

  公开（公告）日：2022-12-22

  Disclosed are methods of treating a cancer and of inducing cell death in an aberrant cancel cell in a subject using a combination of an ATR inhibitor and PARP inhibitor, wherein the PARP inhibitor may be a compound of formula (III) or (IV), or a pharmaceutically acceptable salt thereof; and wherein the cancer/aberrant cell cancer has a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B and/or CDK12; or is an ALT+ cancer/cancer cell. In formula (III): X1and X2are each N or C(H); X3is N and C(R4), R4is H or fluoro; R1is C1-4alkyl or C1-4fluoroalkyl; R2is H, halo, C1-4alkyl, or C1-4fluoroalkyl; and R3is H or C1-4alkyl. In formula (IV): R1is H, C1-4alkyl, C3-6cycloalkyl, C1-4fluoroalkyl, and C1-4fliioroalkyloxy; R2is H, halo, C1-4alkyl, or C1-4fhioroalkyl; R3is H or C1-4alkyl; and R4is halo or C1-4alkyl.